Covance Company Updates |

Company Updates

  • "I’m proud that our company is receiving this important recognition for the third consecutive year,” said Adam H. Schechter, president and CEO of LabCorp. “This is a reflection of our business practices to support workplace equality, but more importantly, our belief that our diverse base of mission-driven employees worldwide is core to our ability to innovate, meet customer needs, and deliver on our mission to improve health and improve lives."

  • Check out our new, state-of-the-art Shanghai R&D Center! Our employees just celebrated the grand opening and are excited to be a part of the only contact research organization (CRO) in China that offers the comprehensive drug development services. Learn about our current job opportunities and join us: #CovancePotential

    Covance jobs in China | Careers at Covance

    Discover all our job opportunities in China and apply for the jobs at Covance in China.

  • LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create Independent Research Model and Services Provider. Read more about the news here.

    Envigo Announcement | Covance

    Expands Covance Capabilities, Creates Independent Research Model and Services Provider

  • We are proud to have earned a rating of 100% on the Human Rights Campaign’s Corporate Equality Index for LGBTQ workplace equality. Learn more about how we foster a culture of inclusion at Covance. #CovancePotential

    Diversity at Covance

    Harnessing diversity for competitive advantage. Inclusion is how we harness the collective richness of our perspectives and expertise to deliver extraordinary performance. Diversity is what we each uniquely bring to our work. It encompasses both what meets the eye, such as race, gender or age, as well as attributes that may not be visible such as nationality, belief, experience and upbringing.

  • LabCorp announces 2018 fourth quarter and full year results, click on the link to learn more.

    Laboratory Corporation of America - Investor Relations - News Release

    The Company has provided in this press release and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted EPS, adjusted operating income, free cash flow, and certain segment information. The Company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the Company's operational performance.

  • LabCorp has been named to Fortune Magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year. Details here:

    Laboratory Corporation of America - Investor Relations - News Release

    BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year.

  • LabCorp acquires Sciformix to expand drug development solutions. “This acquisition strengthens our position in the later phases of drug and device development, particularly for post-marketing pharmacovigilance and market access solutions,” said David P. King, chairman and chief executive officer of LabCorp.

    Laboratory Corporation of America - Investor Relations - News Release

    Sciformix extends Covance's pharmacovigilance capabilities for post-approval safety solutions BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 11, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that it has acquired Sciformix Corporation, a scientific process outsourcing company focused on pharmacovigilance and regulatory solutions for biopharmaceutical and medical devices clients.

  • Working with exceptional people makes all the difference. Learn how employees at our Madison facility are building strong connections and culture. Read it here

Work at Covance? Share Your Experiences

  • Star
  • Star
  • Star
  • Star
  • Star
Click to Rate